Evidence map›Paper›PMID 35257256›Full record

ReviewClinical rheumatology2022

A comprehensive overview of living with Sjögren's: results of a National Sjögren's Foundation survey.

Sara S McCoy, Miguel Woodham, Vatinee Y Bunya, Ian J Saldanha, Esen K Akpek, Matthew A Makara, Alan N Baer

Open access · greenAbstract readReview
In one paragraph

Review in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Radiation-Therapy Related Salivary Dysfunction.Seminars in radiation oncology · 2025
    Review
  10. Article
  11. Review
  12. Cancer therapy-related salivary dysfunction.The Journal of clinical investigation · 2024
    Review
  13. Review
  14. Review
  15. Observational
  16. Therapeutic potential for P2YPurinergic signalling · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Sara S McCoyDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. ssmccoy@medicine.wisc.edu.ORCID http://orcid.org/0000-0002-5293-4185
Miguel WoodhamDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Vatinee Y BunyaDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, PA, USA.
Ian J SaldanhaCenter for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice and Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.ORCID http://orcid.org/0000-0002-2062-3382
Esen K AkpekDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7700-207X
Matthew A MakaraSjӧgren's Foundation, Reston, VA, USA.
Alan N BaerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8344-013X
Johns Hopkins University · USUniversity of Wisconsin–Madison · USBrown University · USRome Foundation · USUniversity of Pennsylvania · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Institutional Career Development CoreKL2TR002374 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Bo Liu, Marin Leigh Schweizer · 2017 to 2026
$9.7M
Developing new methods for early detection of Sjogren's syndromeR01EY026972 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BUNYA, VATINEE Y · 2016 to 2020
$2.0M
NCATS NIH HHS KL2 TR002374NCATS NIH HHS UL1 TR002373NEI NIH HHS R01 EY026972
6 · The paper itself

Abstract

To gain insight into the Sjögren's disease (SjD) patient experience using a survey generated by patients and providers. We evaluated the results of the 2016 Sjögren's Foundation survey, with 25 questions designed in a collaborative effort between the Foundation, patients with SjD, SjD provider experts, and a marketing research company. We used descriptive statistics to provide a thorough understanding of SjD demographics, symptoms, quality of life (QoL), cost, and treatments. Analyses revealed high symptoms, QoL, and financial burdens in SjD. Dry mouth and eye were the most commonly reported symptoms (94 and 93%, respectively). The most frequent extra-glandular symptoms included fatigue, dry or itchy skin, and morning stiffness. The top three aspects of QoL most impaired included (i) sex life (53%), (ii) participating in hobbies/social activities/extracurricular activities (52%), and (iii) job/career or ability to work (49%). SjD respondents commonly reported taking health food supplements/remedies, vitamin D, and exercising, in addition to taking treatments for symptomatic dryness. SjD costs were high, including a total yearly cost, on average, of $2026 for dental care. SjD respondents reported that dryness and risk factors for lymphoma and fatigue are essential to address with new therapies. In this comprehensive overview of the SjD experience, we demonstrated a high burden of disease to SjD respondents, including symptoms, QoL, and financial burden. We also identify the top goals of therapy for new systemic SjD therapies. Key Points • The top three symptoms or signs that patients with Sjögren's hope new treatments will address are dryness, fatigue, and reduction in lymphoma or blood cancer risk • The top aspects of quality of life reported to be impaired by Sjögren's are sex life, hobbies, social activities and extracurricular activities, job/career or ability to work, and finding the correct word during conversations • Patients with Sjögren's have a yearly mean dental cost of $2026 but also have high costs associated with prescription medications, healthcare appointments, over-the-counter medications, alternative therapies, and medical equipment.

Indexed as

Sjogren's SyndromeXerostomiaFatigueHumansQuality of LifeSurveys and QuestionnairesCostQuality of lifeSjӧgren’s diseaseSymptomsTreatment

Identifiers

PMID35257256
PMCPMC9610846
OpenAlexW4221113406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.